Core Scientific, Inc. (NASDAQ: CORZ) announced that it has expanded its 364‑day credit facility to $1 billion, adding a $500 million commitment from JPMorgan Chase Bank, N.A. The new commitment brings the total funded commitments under the facility to $1 billion, matching the previously announced $500 million commitment from Morgan Stanley.
The financing is earmarked for the development of data‑center assets, including equipment purchases, pre‑development costs, real‑property acquisition, and energy procurement for high‑density colocation sites. By securing additional capital, Core Scientific aims to accelerate the conversion of its former Bitcoin‑mining infrastructure into AI and high‑performance computing (HPC) hosting capacity, a shift that underpins its $10 billion CoreWeave contract and broader expansion plans.
Core Scientific’s recent financial performance illustrates the context for this move. In Q4 2025 the company reported revenue of $79.8 million and a gross margin of 26.0 %. For the full year 2025, revenue was $319 million with a gross margin of 11.9 %, while full‑year 2024 revenue was $510.67 million and gross profit was $121.07 million. The data show a decline in revenue but an improvement in margin, reflecting the company’s ongoing transition from mining to higher‑margin colocation services.
The $10 billion CoreWeave contract, which covers roughly 590 megawatts of critical IT load, is a cornerstone of Core Scientific’s strategy. CEO Adam Sullivan emphasized that the new credit facility “provides the flexibility to pursue the CoreWeave contract and other expansion opportunities.” The company is also shifting 500 MW of capacity from Bitcoin mining to HPC, a move that signals a broader pivot toward AI‑driven workloads.
Analysts have responded to the financing by adjusting their coverage. Canaccord raised its price target to $20 from $17, citing the new site acquisition in Texas and power capacity expansions. Needham upgraded its rating to Buy with a target of $23, while Citizens reiterated a Market Outperform rating with a $30 target. Cantor Fitzgerald lowered its target to $25 from $26, maintaining an Overweight rating. These actions reflect a mix of optimism about the company’s growth prospects and caution regarding its historical profitability and power‑access challenges.
The credit‑facility expansion strengthens Core Scientific’s balance sheet and provides the liquidity needed to execute its AI and HPC strategy. While the company faces headwinds such as a negative Altman Z‑Score and tight power access, the new financing positions it to capitalize on the growing demand for high‑density colocation services and to accelerate the deployment of its CoreWeave contract.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.